NGM Biopharmaceuticals In... (NGM)
1.54
-0.02 (-1.28%)
At close: Apr 03, 2024, 3:59 PM
-1.28% (1D)
| Bid | n/a |
| Market Cap | 128.53M |
| Revenue (ttm) | 4.42M |
| Net Income (ttm) | -139.83M |
| EPS (ttm) | -1.73 |
| PE Ratio (ttm) | -0.8901734104046243 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 2,205,569 |
| Avg. Volume (20D) | 1,070,739 |
| Open | 1.56 |
| Previous Close | 1.56 |
| Day's Range | 1.54 - 1.57 |
| 52-Week Range | 0.60 - 4.69 |
| Beta | 1.26 |
About NGM
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that ac...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 4, 2019
Employees 138
Stock Exchange NASDAQ
Ticker Symbol NGM
Website https://www.ngmbio.com